HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Prognostic value of bone and bone marrow lesions of primary myeloid metaplasia].

Abstract
This study of the history of 117 cases of agnogenic myeloid metaplasia with myelofibrosis underlines the importance of anatomo-pathological and radiological parameters for prognosis. Histological staging of bone and bone marrow lesions at time of diagnosis enables one to confirm long survival of cases with hyperplasia (Group I) and more severe prognosis for advanced myelofibrosis (that is both groups II and III considered together) but does not enable to establish a significative difference between medium survival of cach group II and III considered separately. Those medium survivals estimated are the following: 82 months for group I; 60 months for both groups II and III. Thus, it is logical to consider together these two groups among which one can distinguish two anatomoclinical forms. One is characterized by bone marrow hyperplasia with reticulin myelofibrosis and is usually associated with large spleen and even in some cases with polycythemia but without radiologic bone lesions; the other is characterized by bone marrow of medium or hypoplasic constitution fibrosis, with or without osteosclerosis and with radiologic bone lesions of mode-rate or important extension (respectively 16.9 p. cent of cases) and is usually associated with pancytopenia.
AuthorsN Chelloul, C Jacquillat, J Brière, M Laval-Jeantet, W Vorhauer-Atlan
JournalLa Nouvelle presse medicale (Nouv Presse Med) Vol. 4 Issue 43 Pg. 3060-2 (Dec 13 1975) ISSN: 0301-1518 [Print] France
Vernacular TitleValeur pronostique des lésions ostéo-médullaires de la splénomégalie myéloïde primitive
PMID1223788 (Publication Type: English Abstract, Journal Article)
Topics
  • Bone Marrow (pathology)
  • Bone Marrow Examination
  • Bone and Bones (pathology)
  • Fibroblasts
  • Follow-Up Studies
  • Humans
  • Hyperplasia
  • Megakaryocytes
  • Osteolysis (diagnosis)
  • Primary Myelofibrosis (diagnosis)
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: